Life Sciences Archivi - Pagina 13 di 16

6 giugno 2023

North America ISOs Medical Device and Equipment Maintenance and Calibration Services Market Was Dominated in the U.S.

The North America ISOs medical device and equipment maintenance and calibration services market will grow at a rate of 8.9% in the years to come, to reach USD 3,612.9 million by 2030, as stated by a market research institution, P&S Intelligence.

The key factors responsible for the industry growth are progressions in the medical device sector, increase in consciousness regarding preventive medical equipment maintenance, and strict regulatory environment.

The patient monitoring and electromedical category will grow the fastest in the years to come. This has a lot to do with the high incidence of chronic ailments, such as cardiac and respiratory, increasing aging population, and growing number of ICU beds.

The U.S. had a larger share in the North America ISOs medical device and equipment maintenance and calibration services market, and the nation will continue the same way in the years to come. This is mostly because of the occurrence of a large count of hospitals and established players and rise in tech progressions with regards to diagnostic tests.

Medical devices can be employed in numerous applications, not being precise to just one area.

Furthermore, these services also aid in averting infections brought about by the usage of medical devices throughout surgeries.

Therefore, the importance on cleanliness in healthcare institutions is increasing, with a number of prestigious administrations delivering guidance for improving cleanliness and averting infections.

For example, the WHO has given guidelines for hospital hygiene, emphasizing equipment maintenance for infection control.

The incidence of a strict regulatory framework makes medical paraphernalia maintenance a required prerequisite for end users in North America.

For instance, the U.S. CMS regulations and other accreditation necessities TJC, HFAP, and DNV, along with guidelines by OEMs and the USFDA, necessitate compliance with regards to equipment maintenance amongst hospitals.

It is because of the advancements in medical industry, the demand for medical device and equipment maintenance and calibration services in North America will be on the rise in the years to come.

6 giugno 2023

Medical Cartridges Industry Will Grow Fastest in the Asia-Pacific Region

The medical cartridges market will grow at a rate of 6.4% in the years to come to touch a value of USD 1,691.1 million by 2030. The factors accountable for the growth of the industry are growing pharma sector and increasing requirement for injectable pharma products.

Also, the surging elderly population and increasing occurrence of chronic and acute diseases will boost the requirement for medical cartridges all over the world.

On the basis of material type, the industry is categorized into plastic and glass. The glass category had larger share in the past, as stated by a market expert at P&S Intelligence.

Europe had the largest share in the medical cartridges market in the recent past. This is mostly credited to the increasing occurrence diabetes.

Also, deskbound lifestyle of people in the region is the main reason for obesity. For example, as per the IDF Diabetes Atlas Ninth Edition, about 59 million adults, who were aged 20–79 years suffered from diabetes in 2019.

Alternatively, APAC will grow the fastest in the years to come, because of the growing elderly population in the region, increasing incidence of diabetes, and expanding healthcare spending.

The growing pharma sector has an important role to play in the growth of the industry. The industry manufactures biologics and biosimilar drugs for managing a number of chronic diseases, for example diabetes, cancer, and rheumatoid arthritis. Some biopharma products are advanced and manufactured in the form of injectable therapeutic agents, administered through cartridges, vials, and prefilled syringes.

It is because of the aging elderly population around the world, and the developing pharma industry, the demand for medical cartridges will continue to grow in the years to come, globally.

5 giugno 2023

Lip Cold Sore Treatment Industry Was Dominated by Creams

The lip cold sore treatment market had a revenue in China, South Korea, Taiwan, Hong Kong, and SEA grow at a rate of 6.7% in the years to come to reach USD 85,265.1 Thousand by 2030 as mentioned in one of its reports by a market research institution, P&S Intelligence.

The important factors accountable for the industry growth include the thriving modes of transmission of HSV, growing incidence of cold sores, and progressions in treatments with the increasing count of product launches.

Cream dominated the industry, on the basis of product type. Also, the category will retain its position in the years to come as a result of the fact that creams is good for healing the sores fast and decrease itching, tingling, pain, and burning.

China had the largest contribution in the industry. This will also grow the fastest in the years to come. This is because of the growing incidence of HSV-1 infection amongst the rural people in the nation, presence of key industry players, and increasing consciousness of the disease.

As per a study directed by the IDEG at WCM-Q, HSV-1 is majorly transmitted through mouth to-mouth contact, therefore bringing about an infection on or around the mouth, which is recognized as oral herpes.

Furthermore, asymptomatic and symptomatic viral shedding are highly common, which has allowed the virus to be transmitted additionally, at a high pace.

The market is fragmented in nature, and the major players are involved in a number of mergers and acquisitions.

It is because of the growing prevalence of cold sores, the demand for lip cold sore treatments will continue to grow in the years to come.

5 giugno 2023

Growth of the Gene Therapy Market in Asia-Pacific

The Asia-Pacific gene therapy market will power at a rate of 36.8% in the years to come to reach USD 6,931.5 million by 2030, as stated by a market research institution, P&S Intelligence.

The factors responsible for market growth are the growing gene therapy development activities, surging chronic diseases burden, and growing count of clinical trials with positive results.

The adenovirus category will grow the fastest growth in the years to come, on the basis of vector type. This will mostly be as a result of the high level of expressions and high transduction competence of these kind of vectors.

The carcinoma category led the industry. As per the GLOBOCAN, 2.3 million cases of cancer were stated in Southeast Asia and 1.4 million people lost their lives as a result of it in 2020.

China had the highest revenue in the industry and it will maintain its position in the future. This has a lot to do with the increasing count of strategic expansions amongst main companies and snowballing occurrence of cancer and rare ailments.

The increasing participation of private and public research institutions in gene therapy research is responsible for powering the growth of the industry in APAC. As a result of the rapid tech progressions over decades, the expansion of gene therapies has recuperated momentous interest.

This procedure is being proficient by the optimization of vectors, for example lentiviruses and retroviruses, by the initiation of novel procedures, for example induced pluripotent stem cells, in combination with the prevailing models of gene editing and even by trials in germ cells.

It is because of the positive clinical trials results, the requirement for gene therapy in the APAC region will continue to increase in the years to come.

2 giugno 2023

Interventional Vascular Consumables Industry Growth and Demand Forecast to 2030

The total value of the global interventional vascular consumables market was USD 3,929.2 million in 2021, and it will rise at a growth rate of above 3.8% shortly, reaching USD 5,501.7 million by 2030, according to P&S Intelligence.

This growth can be attributed to the growing count of CVD cases throughout the world is boosting the need for interventional vascular procedures. For example, as per the WHO, approximately 17.9 million individuals expire of CVDs per annum, representing 32.0% of all worldwide demises.

In 2021, the consumables utilized in coronary interventional events generated the highest revenue share of approximately 80%. The growing occurrence of coronary heart illness, related to the growing elderly populace, is directing to the rising demand for the consumables utilized during coronary procedures.

In 2021, North America dominated the interventional vascular consumables market with the largest share, 35.2%. The supremacy of the region in the industry is majorly credited to the increasing healthcare investments, growing count of cases of chronic illnesses, and increasing elderly populace.

As per a report in the U.S., issued by the Rural Health Information Hub, 46 million individuals were aged 65 and more in 2020, and this count is set to surge to nearly 90 million by 2050. The thriving elderly populace leads to the increasing occurrence of chronic illnesses, therefore causing a high requirement for interventional vascular consumables in the continent.

Interventional procedures are favored by elder patients as such procedures have a lesser danger of complications and are inexpensive. Furthermore, they are chosen as with age, patients’ capability to heal the marks of the operation might reduce.

Hence, the growing count of CVD cases throughout the world is boosting the need for interventional vascular procedures.

1 giugno 2023

Pharmacogenomics Market Size, Industry Shares, Global Growth and Analysis 2030

The revenue generated by the pharmacogenomics market will power at a 7.4% rate by the end of this decade, to reach USD 10,505.3 million by 2030.

The industry growth is because of the growing incidence of infectious diseases and various cancers, increasing acceptance of personalized medicine, a shift from reaction to prevention globally, increasing rate of opposing drug reactions, and growing use of pharmacogenomics in medicine discovery and development.

Genotyping services had the largest share, of about 45%. This has a lot to do with the recommendations of health providers globally obtaining individual genomic profiles, for catering to the continuously developing healthcare requirements.

The PCR technology accounted for above 45% share. This has a lot to do with the fact that PCR makes use of a small sample for analysis, for detecting microbial agents, and the procedure takes approximately 4–8 hours, which is about three times faster than further methods.

Moreover, multiplex PCR is a kind of PCR that might amplify numerous DNA sequences in a single reaction. It has been routinely used for identification of a number of antibiotic genes.

Moreover, PCR has established higher sensitivity and positivity rates than culture and stains for bacteria and fungi.

The acceptance of sequencing will grow the fastest with a rate of approximately, 8% by the end of this decade. This will chiefly be because of the growing emphasis on sequencing analysis for diverse genomic patterns.

North America pharmacogenomics market was the leader, and it will continue to grow at a rate of over 7%, in the years to come. The surge in the acceptance of pharmacogenomic practices is powered by the initiatives taken by the government for including targeted medicine methods in the healthcare system.

Furthermore, the U.S. FDA and the CLIA have led the development of effective and apt guidelines and policies for propelling the acceptance of pharmacogenomic tests by users.

Because of the increasing cases of infectious diseases around the world, the demand for pharmacogenomics will continue to grow by the end of this decade.

25 maggio 2023

North America Leads the Ligases Enzyme Industry

The total size of the ligases enzyme market was about USD 367.4 million in the recent past, and it will power at a rate of 6.2% for reaching USD 631.7 million by 2030, as stated by P&S Intelligence.

T4 DNA ligase dominated the industry in the recent past. It will grow at a rate of 6.8% in the years to come.

T4 DNA ligase is extensively put to use in a number of settings for effective and quick litigation, as it has the potential to litigate cohesive-ended and blunt double stranded fragments of DNA, coupled with T/A cloning.

The molecular cloning category dominated the ligases enzyme market and it will generate USD 134.8 million by the end of this decade, growing at a rate of 6.8%.

This cloning is a set of scientific procedures in molecular biology, and is put to use for combining recombinant DNA molecules and their straight replacement in the host creature.

Moreover, there are various applications of molecular cloning, such as stem cell cloning , helping provide treatment for numerous ailments, a better comprehension of elderly and other ailments.

Apart from this NGS category had a revenue of about 14% in the past, and it will also exhibit a considerable rate of growth. The NGS technologies have progressive recompenses, with regard to high-sequencing speed, high-resolution, accuracy and cost-effectiveness in genomic analysis.

The rising cases of chronic conditions, including cancers is powering the demand and interest of people in innovating treatment strategies, providing better care to patients.

DNA repair abnormalities in inherited illnesses, manifesting as cancer propensity include breast cancer and hereditary kinds of colon. In hereditary breast cancers, poly polymerase inhibitors function as a therapy directly targeting DNA repair deficiency.

North America had the largest share in the industry of USD 224.7 million, and it will consolidate its position in the years to come as well, because of an increase in the activities pertaining to research and development for developing ligases as therapeutic agents for cancer and other ailments.

It is because of the increasing prevalence of cancer and other diseases related to old age, the demand for ligases enzyme will continue to grow even more in the near future.

25 maggio 2023

North America Is Dominating Pressure Relief Devices Industry

In 2021, the pressure relief devices market was worth around USD 3,361.1 million, and it is projected to advance at a 6.5% CAGR from 2021 to 2030, hitting USD 5,923.9 million in 2030, according to P&S Intelligence.

This growth can be ascribed to the factors such as, they are simple to utilize, cost-effective, and extremely effective in averting ulcers, with foam mattresses experiencing the highest demand. By 2030, the quickest development will be in the acceptance of gel-based mattresses, as they are better than other kinds of low-tech devices.

In 2021, low-tech devices held the largest market share, at approximately 65%, and they are projected to continue to dominance in the future as well.

This can be credited to the simple useability, high effectiveness in preventing ulcers, and low cost. Among the low-tech devices, form-based devices are the key stakeholders as they absorb the pressure movement, which supports uninterrupted sleep.

The U.S. in North America, is the largest Pressure Relief Devices Market with a share, of approximately 37%. The nation has a high occurrence of pressure ulcers, supportive medical grants scenario, and numerous government subsidy schemes.

Western Europe has the second largest revenue contribution by Europe due to the large population with pressure ulcers. Additionally, many government and non-governmental organizations run campaigns to raise awareness of the condition.

APAC is the third-highest revenue generator and is projected to experience a CAGR of 7.2%, in the coming years. Key players are joining hands with local sellers in India, China, and South Korea to aim for a vast customer base here and surge their sales.

Hence, pressure relief devices are simple to utilize, cost-effective, and extremely effective in averting ulcers, and also the large population with pressure ulcers, such factors are propelling the Pressure Relief Devices industry.

24 maggio 2023

North America Ambulatory Infusion Pumps Industry Growth Forecast Report 2030

In 2021, the North American ambulatory infusion pumps market was worth around $953.1 million, and it is expected to reach $1,989.8 million by 2030, advancing at an 8.5% CAGR from 2021 to 2030.

The major factors behind the industry growth are the rising geriatric population, snowballing diabetes incidence, surging demand for ambulatory services, and growing prevalence of many other chronic diseases.

The industry growth is also ascribed to the rising awareness about diabetes management and increasing healthcare expenditure. Insulin and obesity resistance have been taken as separate risk factors for diabetes; therefore, the growing obese populace results in a massive demand for insulin delivery devices, which, in turn, boosts the ambulatory infusion pump sales in North America.

Accessories & Consumables Hold Larger Share in Market

Accessories & consumables capture the larger share of the industry, based on product type. It is ascribed to their repetitive buying and presence of a wide range of accessories & consumables across North America.

In 2021, devices too had a significant market share. This can be credited to the surging demand for such pumps for convenience when taking drugs for a wide range of conditions.

Largest Share Is Captured by Diabetes Application

Diabetes holds the largest revenue share of the North American ambulatory infusion pumps market, around 30%, based on application. This can be credited to the rising incidence of diabetes and its complications in the region.

Around 96 million people in the age group of 18 and above suffer from prediabetes, which amounts to 38.0% of the adult U.S. population. As insulin needs to be injected at specific times, an infusion pump replaces the need for numerous regular injections with a single constant infusion.

Ambulatory Service Demand Rising Rapidly

The rising geriatric population and increasing stress on healthcare organizations because of the burgeoning number of patients afflicted with all kinds of diseases are significantly driving the popularity of ambulatory services in the region. This is also ascribed to the low cost of these services and their higher suitability compared to conventional hospital services.

Thus, the count of ambulatory surgical centers in the U.S. has significantly increased in the last few years. The acceptance of ASCs can also be credited to the faster recovery, lower infection risk, shorter stays, and innovative technologies they offer.

The U.S. holds a gigantic share, of over 90%, due to the availability of key players, surging prevalence of chronic diseases, developed healthcare infrastructure, and favorable reimbursement policies. Additionally, the expansion in the count of healthcare settings and the availability of home infusion services propel the industry’s growth.

As per the American Hospital Association, 6,093 hospitals were active in the U.S. in 2021, including 2,960 non-government hospitals and 1,228 investor-owned healthcare facilities.

23 maggio 2023

North America Is Dominating Rapid Test Kit Industry

In 2022, the rapid test kit market was worth around USD 23,043.3 million, and it is projected to advance at a 9.1% CAGR from 2022 to 2030, hitting USD 46,139.9 million in 2030, according to P&S Intelligence.

Rapid tests are utilized for initial screening, and for the initial analysis of illnesses. Because of their dependability and quick results, they have extensive applications.

Furthermore, credited to their lucrative and easy-use nature, the diagnoses can be completed with ease of one’s home, which is another factor they are gaining more and more traction in the industry. The increasing infectious disease occurrence, surge in the importance of knowledge of early diagnoses, and growing elderly populace positively impacted the demand for such tests.

The outburst of the novel coronavirus resulted in the sudden and massive development of the industry, because of the growth in the need for quick diagnostic solutions, to eventually stop the serious, life-intimidating difficulties of the virus.

The terror of infectious infection results in individuals accepting such quick point-of-care diagnostic kits to identify the virus early stage, from the ease of their houses. The orders for the accessibility of such kits by governments at several public and private hospitals also boosted the growth of the market.

The increasing frequency of foodborne illnesses leads to a surge in the utilization of rapid diagnostic kits to classify the existence of contaminants, through the testing of a food sample, to avoid difficulties.

Benefits like, specificity, high sensitivity, fast results the capability to spot viruses existing to a low extent, and the removal of the restrictions of orthodox testing approaches make enhanced rapid tests more popular, thus fuelling the market growth. Furthermore, such diagnostic tests are enabled to remove human mistakes, save time and reduce labor.

In 2022, the hospitals and clinics category held the largest rapid test kit market share, of around 50%, on the basis of end users. This can be credited to the surging occurrence of the novel coronavirus infection caused a high hospitalization rate. This multitudes the number of partnerships between the main industry players and several steps by governments worldwide to guarantee the accessibility of test kits for the initial diagnosis of COVID-19, to avoid further damages.

North America had the largest market share, of approximately 45%, in 2022. This can be credited to the existence of deep-rooted medicinal companies in the continent, strong healthcare infrastructure, and high knowledge among the people regarding maintaining well-being.

Hence, with the help of these kits, the diagnoses can be completed with ease of one’s home and also the increasing infectious disease occurrence, the surge in the importance of knowledge of early diagnoses, and the growing elderly populace are major factors driving the rapid test kit market.